SARS-CoV-2 Universal Total Antibody Assay

Universally applicable IT assay for total antibodies in COVID-19

Quantitative determination of antibodies to SARS-CoV-2 is becoming increasingly important as it provides a good assessment of the actual spread of COVID-19 infections. It plays an important role in characterizing a vaccine-induced immune response and allows quantification of antibody levels in plasmapheresis donations used to treat COVID-19 patients with a severe course.

SARS-CoV-2 UTAB FS is an immunoturbidimetric test to determine total antibodies in human serum. The test is characterized by high specificity and sensitivity and shows no cross-reactivity with antibodies present to other seasonal cold pathogens from the corona virus group (OC43, 229E, NL63, HKU1).

The test provides comparable results on almost all clinical chemistry analyzers. It enables reliable monitoring of patients, which is currently a major challenge, especially in the context of testing the efficacy of new vaccines, as available antibody tests have different reaction principles and can usually only be used on the manufacturers’ platforms.

The liquid stable, ready-to-use reagent with matched calibrators, controls and sample dilution matrix is available now.

Features

• Detection of SARS-CoV-2 S1-RBD-targeting antibodies
• High specificity and sensitivity
• No cross-reactivity to coronaviruses causing common cold
• Universally applicable assay that delivers comparable results, regardless of the device used
• Quantitative assay for total antibody detection in COVID-19
• High throughput PETIA (Particle enhanced immunoturbidimetric assay)
• Liquid-stable, ready-to-use reagent with dedicated calibrators and controls